促燃剂相关烧伤与药物滥用:具有挑战性的组合
该回顾性病例对照研究分析了2009至2014年不列颠哥伦比亚烧伤登记处中促燃剂相关烧伤患者,占所有烧伤入院患者的28.2%(N=532)。与非促燃剂组相比,促燃剂组有药物滥用史者比例更高,并与更大的TBSA烧伤面积、呼吸机支持、ICU停留及肺炎发生率相关。促燃剂组内有或无药物滥用史者的临床结局无差异。
要点
- 促燃剂相关烧伤占烧伤入院的28.2%(N=532)。
- 促燃剂组较非促燃剂组有更高比例的药物滥用史,并与更大TBSA、呼吸机支持、ICU停留及肺炎率相关。
- 促燃剂组内有或无药物滥用史者的临床结局无差异;4例与甲基苯丙胺制造相关,均需ICU停留和呼吸机支持。
核心结论
- 促燃剂相关烧伤给烧伤中心带来显著负担,其中相当比例患者有药物滥用史。
- 促燃剂组内有或无药物滥用史者的临床结局无差异。
研究设计与样本
- 回顾性病例对照研究,数据来自不列颠哥伦比亚烧伤登记处2009至2014年促燃剂相关烧伤患者,并与非促燃剂相关烧伤对照组比较。
- 采用卡方检验评估分类数据,Student t检验评估均值定量数据,p值设为0.05,并采用逻辑回归模型评估影响烧伤并发症的因素。
主要发现
- 促燃剂相关烧伤占2009至2014年所有烧伤入院的28.2%(N=532)。
- 与非促燃剂组相比,促燃剂组有药物滥用史者比例更高,并与更大TBSA烧伤、呼吸机支持、ICU停留及肺炎发生率更高相关。
- 在促燃剂组内,有或无药物滥用史者的临床结局无差异。
- 4例与甲基苯丙胺制造相关,均接受了ICU停留和呼吸机支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Accelerants are flammable substances that may cause explosion when added to existing fires. The relationships between drug abuse and accelerant-related burns are not well elucidated in the literature. Of these burns, a portion is related to drug manufacturing, which have been shown to be associated with increased burn complications. OBJECTIVES: 1) To evaluate the demographics and clinical outcomes of accelerant-related burns in a Provincial Burn Centre. 2) To compare the clinical outcomes with a control group of non-accelerant related burns. 3) To analyze a subgroup of patients with history of drug abuse and drug manufacturing. METHODS: Retrospective case control study. Patient data associated with accelerant-related burns from 2009 to 2014 were obtained from the British Columbia Burn Registry. These patients were compared with a control group of non-accelerant related burns. Clinical outcomes that were evaluated include inhalational injury, ICU length of stay, ventilator support, surgeries needed, and burn complications. Chi-square test was used to evaluate categorical data and Student's t-test was used to evaluate mean quantitative data with the p value set at 0.05. A logistic regression model was used to evaluate factors affecting burn complications. RESULTS: Accelerant-related burns represented 28.2% of all burn admissions (N=532) from 2009 to 2014. The accelerant group had higher percentage of patients with history of drug abuse and was associated with higher TBSA burns, ventilator support, ICU stay and pneumonia rates compared to the non-accelerant group. Within the accelerant group, there was no difference in clinical outcomes amongst people with or without history of drug abuse. Four cases were associated with methamphetamine manufacturing, all of which underwent ICU stay and ventilator support. CONCLUSIONS: Accelerant-related burns cause significant burden to the burn center. A significant proportion of these patients have history of drug abuse.
引用
- Leung LTF, Papp A. Accelerant-related burns and drug abuse: Challenging combination. Burns. 2018. PMID: 29100677. doi:10.1016/j.burns.2017.10.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。